Consistent with these meta-analytic findings, an OHDSI multi-database cohort observed no difference in the risk of kidney failure among bevacizumab, ranibizumab, and aflibercept; the authors noted no empirical basis to prefer one agent for kidney protection and recommended monitoring kidney health during intravitreal anti-VEGF therapy (Cai et al., 2024). Here, VEGFA is linked to kidney failure.